CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that the executive management team will present and host meetings with investors at the virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February.
Pablo J. Cagnoni, M.D., president and chief executive officer, will provide a corporate update through fireside chats at Guggenheim Healthcare Talks | Idea Forum | Oncology Day on February 10, 2022, 08:00 a.m. EST and at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, 1:00 p.m. EST. Live audio webcasts for these events will be available within the Investors & Media section of the Rubius Therapeutics website. Archived replays will be accessible for 90 days following the events.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to biologically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the 2021 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2021 Best Places to Work in Rhode Island by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.
Elhan Webb, CFA, VP Investor Relations
Marissa Hanify, Director, Corporate Communications
Source: Rubius Therapeutics